Jonathan Uy

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Jonathan Uy
    Section of Infectious Diseases, University of Illinois College of Medicine, Chicago, IL, USA
    Antivir Ther 12:957-62. 2007
  2. ncbi Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure
    Jonathan Uy
    University of Illinois, Chicago, IL, USA
    J Acquir Immune Defic Syndr 51:450-3. 2009
  3. ncbi Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine
    Jonathan Uy
    Bristol Myers Squibb, Research and Development, Plainsboro, USA
    AIDS Care 23:1500-4. 2011
  4. ncbi Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing
    Max Lataillade
    Research and Development, Bristol Myers Squibb, Wallingford, Connecticut, United States of America
    PLoS ONE 7:e30118. 2012
  5. ncbi Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study
    Max Lataillade
    Global Development and Medical Affairs, Bristol Myers Squibb, Wallingford, Connecticut, USA
    PLoS ONE 5:e10952. 2010
  6. ncbi Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy
    Richard M Novak
    University of Illinois, Chicago, IL 60612, USA
    Clin Infect Dis 40:468-74. 2005
  7. ncbi Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine
    Thomas C Stoeckli
    Division of Infectious Diseases, Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver 80262, USA
    Antimicrob Agents Chemother 46:4000-3. 2002
  8. ncbi The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies
    Michael J Kozal
    Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut 06510, USA
    HIV Clin Trials 8:357-70. 2007
  9. ncbi Moving forward in HIV medicine
    Jonathan Uy
    University of Illinois at Chicago, USA
    Posit Aware 14:32-3. 2003

Detail Information

Publications9

  1. ncbi HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Jonathan Uy
    Section of Infectious Diseases, University of Illinois College of Medicine, Chicago, IL, USA
    Antivir Ther 12:957-62. 2007
    ..Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization...
  2. ncbi Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure
    Jonathan Uy
    University of Illinois, Chicago, IL, USA
    J Acquir Immune Defic Syndr 51:450-3. 2009
    ..There are limited data on the risk of developing HIV drug resistance based on the CD4 cell count at which highly active antiretroviral therapy (HAART) is initiated...
  3. ncbi Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine
    Jonathan Uy
    Bristol Myers Squibb, Research and Development, Plainsboro, USA
    AIDS Care 23:1500-4. 2011
    ..These results highlight the importance of tolerability of antiretroviral therapy (ART) in the patients at greatest risk of morbidity and mortality when using regimens of similar potency...
  4. ncbi Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing
    Max Lataillade
    Research and Development, Bristol Myers Squibb, Wallingford, Connecticut, United States of America
    PLoS ONE 7:e30118. 2012
    ..CASTLE compared the efficacy of atazanavir/ritonavir (ATV/r) with lopinavir/ritonavir (LPV/r), each in combination with TVD in ARV-naïve subjects...
  5. ncbi Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study
    Max Lataillade
    Global Development and Medical Affairs, Bristol Myers Squibb, Wallingford, Connecticut, USA
    PLoS ONE 5:e10952. 2010
    ..CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with tenofovir-emtricitabine in ARV-naïve subjects from 5 continents...
  6. ncbi Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy
    Richard M Novak
    University of Illinois, Chicago, IL 60612, USA
    Clin Infect Dis 40:468-74. 2005
    ..However, it is unclear to what extent these mutations persist in chronically infected, treatment-naive patients...
  7. ncbi Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine
    Thomas C Stoeckli
    Division of Infectious Diseases, Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver 80262, USA
    Antimicrob Agents Chemother 46:4000-3. 2002
    ..Sequences from the Stanford HIV RT and Protease Sequence Database showed that these mutations were more common in HIV-1 isolates from patients treated with zidovudine and lamivudine than in patients not treated with these drugs...
  8. ncbi The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies
    Michael J Kozal
    Yale University School of Medicine and VA CT Healthcare System, New Haven, Connecticut 06510, USA
    HIV Clin Trials 8:357-70. 2007
    ..The strategies were compared for drug resistance at first virologic failure (VF; HIV RNA >1000 copies/mL). The impact of resistance on AIDS or death was determined...
  9. ncbi Moving forward in HIV medicine
    Jonathan Uy
    University of Illinois at Chicago, USA
    Posit Aware 14:32-3. 2003